Disaggregated Revenues

6 Months Ended

Jun. 30, 2021

Disaggregation of Revenue [Abstract]

Disaggregated Revenues

Disaggregated Revenues

The following table summarizes the disaggregation of revenues by product or source, (dollars in thousands):

	Three Months ended June 30,				Six Months ended June 30,
	2021		2020		2021		2020
	(unaudited)				(unaudited)
Net product sales
Trokendi XR	$	78,777	$	89,674	$	150,596	$	158,225
Oxtellar XR	25,022		23,680		52,392		47,619
APOKYN	26,981		8,600		48,711		8,600
MYOBLOC (1)	4,641		1,229		8,881		1,229
XADAGO	2,892		801		6,114		801
Qelbree	315		—		315		—
Total net product sales	$	138,628	$	123,984	$	267,009	$	216,474
Royalty revenues	2,701		2,745		5,252		5,231
Total revenues	$	141,329	$	126,729	$	272,261	$	221,705

______________________________

(1) In April 2021, the Company notified the European Medicine Agency that it will cease the marketing of rimabotulinumtoxinB in European countries where it has been marketed as NeuroBloc.

Trokendi XR accounted for 57% and 56% of the Company’s total net product sales for the three and six months ended, June 30, 2021, respectively, and approximately 73% of the Company's total net product sales for both the three and six months ended, June 30, 2020.

The Company's three major customers, AmerisourceBergen Drug Corporation, Cardinal Health, Inc. and McKesson Corporation, individually accounted for more than 25% of our total net product sales and collectively accounted for more than 85% of our total net product sales in both 2021 and 2020.

The Company recognized noncash royalty revenue of $2.2 million and $4.4 million, for the three and six months ended June 30, 2021, respectively. The Company recognized noncash royalty revenue of $2.3 million and $3.9 million, for the three and six months ended June 30, 2020, respectively. Refer to Note 15, Commitments and Contingencies.